Price$87.01-0.86 (-0.98%)
01:30 PM07:45 PM
News · 26 weeks100-85%
2025-12-072026-05-31
Mix5090d
- Insider22(44%)
- Other14(28%)
- SEC Filings10(20%)
- Earnings2(4%)
- M&A1(2%)
- Analyst1(2%)
Latest news
25 items- SECSEC Form SD filed by Abbott LaboratoriesSD - ABBOTT LABORATORIES (0000001800) (Filer)
- PRAbbott secures CE Mark for world's first dual glucose-ketone sensing technology for people with diabetesFirst-of-its-kind biowearables combine continuous glucose and ketone monitoring in a single sensor to support both daily diabetes management and help detect rising ketone levels that can lead to diabetic ketoacidosis, a serious health condition for people with diabetesIntegrates with the Libre digital health ecosystem, allowing people to share glucose and ketone data with caregivers and healthcare providersDesigned for compatibility with leading automated insulin delivery (AID) systemsABBOTT PARK, Ill., May 27, 2026 /PRNewswire/ -- Abbott (NYSE:ABT), a global healthcare leader, announced today it has secured CE Mark for the world's first dual glucose‑ketone sensing technology for people with
- PRACS guideline reaffirms Abbott leadership in noninvasive colorectal cancer screeningCologuard® and Cologuard Plus® reaffirmed as preferred options for noninvasive colorectal cancer (CRC) screening in updated American Cancer Society guidelineAbbott to offer only CRC screening portfolio aligned to new ACS recommendations combining preferred stool-based plus additional blood-based optionsRecent publications support Cologuard-first strategy, demonstrating better outcomes for patients, providers, health systems, and payersABBOTT PARK, Ill., May 27, 2026 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that the American Cancer Society (ACS) has released updated colorectal cancer (CRC) screening guidelines that reaffirm Cologuard® and Cologuard Plus® as preferred noninvasive scr
- PRAbbott showcases expanding evidence across its cancer diagnostics portfolio at ASCO 2026Data highlight how screening and diagnostics enable earlier detection, more precise treatment decisions, and improved patient outcomes from risk to remissionNew MRD data from the PARTNER study demonstrate enhanced sensitivity in early triple-negative breast cancerEarly MCED prospective data show low anxiety and minimal psychological burden in real-world useABBOTT PARK, Ill., May 26, 2026 /PRNewswire/ -- Abbott (NYSE:ABT) will present 11 abstracts featuring new evidence across the cancer care continuum at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 29 – June 2, 2026, in Chicago. The presentations showcase the breadth of Abbott's integrated cancer diagnost
- INSIDERSEC Form 4 filed by EXECUTIVE VICE PRESIDENT Moreland Mary K4 - ABBOTT LABORATORIES (0000001800) (Issuer)
- SECSEC Form SCHEDULE 13G filed by Abbott LaboratoriesSCHEDULE 13G - ABBOTT LABORATORIES (0000001800) (Subject)
- SECSEC Form 10-Q filed by Abbott Laboratories10-Q - ABBOTT LABORATORIES (0000001800) (Filer)
- INSIDERDirector Conroy Kevin T was granted 2,286 units of Common shares without par value, increasing direct ownership by 2% to 133,737 units (SEC Form 4)4 - ABBOTT LABORATORIES (0000001800) (Issuer)
- INSIDERNew insider Conroy Kevin T claimed ownership of 131,451 units of Common shares without par value (SEC Form 3)3 - ABBOTT LABORATORIES (0000001800) (Issuer)
- INSIDERDirector Stratton John G was granted 2,286 units of Common shares without par value, increasing direct ownership by 12% to 21,319 units (SEC Form 4)4 - ABBOTT LABORATORIES (0000001800) (Issuer)
- INSIDERDirector Starks Daniel J bought $926,537 worth of Common shares without par value (10,000 units at $92.65) and was granted 2,286 units of Common shares without par value, increasing direct ownership by 0.18% to 6,751,103 units (SEC Form 4)4 - ABBOTT LABORATORIES (0000001800) (Issuer)
- INSIDERDirector Roman Michael F was granted 2,286 units of Common shares without par value, increasing direct ownership by 27% to 10,764 units (SEC Form 4)4 - ABBOTT LABORATORIES (0000001800) (Issuer)
- INSIDERDirector O'Grady Michael was granted 2,286 units of Common shares without par value, increasing direct ownership by 43% to 7,603 units (SEC Form 4)4 - ABBOTT LABORATORIES (0000001800) (Issuer)
- INSIDERDirector Mckinstry Nancy was granted 2,286 units of Common shares without par value, increasing direct ownership by 6% to 41,010 units (SEC Form 4)4 - ABBOTT LABORATORIES (0000001800) (Issuer)
- INSIDERDirector Mcdew Darren W was granted 2,286 units of Common shares without par value, increasing direct ownership by 22% to 12,678 units (SEC Form 4)4 - ABBOTT LABORATORIES (0000001800) (Issuer)
- INSIDERDirector Kumbier Michelle was granted 2,286 units of Common shares without par value, increasing direct ownership by 15% to 18,000 units (SEC Form 4)4 - ABBOTT LABORATORIES (0000001800) (Issuer)
- INSIDERDirector Gonzalez Patricia Paola was granted 2,286 units of Common shares without par value, increasing direct ownership by 33% to 9,205 units (SEC Form 4)4 - ABBOTT LABORATORIES (0000001800) (Issuer)
- INSIDERDirector Blount Sally E. was granted 2,286 units of Common shares without par value, increasing direct ownership by 7% to 36,344 units (SEC Form 4)4 - ABBOTT LABORATORIES (0000001800) (Issuer)
- INSIDERDirector Babineaux-Fontenot Claire was granted 2,286 units of Common shares without par value, increasing direct ownership by 43% to 7,603 units (SEC Form 4)4 - ABBOTT LABORATORIES (0000001800) (Issuer)
- INSIDERDirector Ahuja Nita was granted 2,286 units of Common shares without par value (SEC Form 4)4 - ABBOTT LABORATORIES (0000001800) (Issuer)
- PRAbbott receives FDA clearance and CE Mark for next-generation Ultreon™ 3.0 AI-powered coronary imaging platformUltreon 3.0 is the first advanced optical coherence tomography (OCT) system in the U.S. and Europe that integrates high resolution coronary plaque images and AI-automated insights through the arteryThe integrated imaging platform is designed to enable fast, intuitive decision making for physicians while treating complex coronary disease to open clogged arteriesThe AI enabled software helps physicians size and position the stent more accurately, which can lead to better results for patientsABBOTT PARK, Ill., April 28, 2026 /PRNewswire/ -- Abbott (NYSE:ABT) today announced it received U.S. Food and Drug Administration (FDA) clearance and CE Mark for its next-generation Ultreon™ 3.0 Software. T
- INSIDEREVP AND CFO Boudreau Philip P bought $201,300 worth of Common shares without par value (2,200 units at $91.50) (SEC Form 4)4 - ABBOTT LABORATORIES (0000001800) (Issuer)
- SECAbbott Laboratories filed SEC Form 8-K: Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - ABBOTT LABORATORIES (0000001800) (Filer)
- PRAbbott showcases strength of its technologies to address abnormal heart rhythms with late-breaking clinical data at Heart Rhythm Society 2026Four late-breaking presentations at Heart Rhythm Society 2026 in Chicago highlight strong clinical evidence across Abbott's growing pulsed field ablation and novel cardiac pacing portfoliosSix-month results from the FlexPulse IDE study for the TactiFlex™ Duo Ablation Catheter, Sensor Enabled™, reveal positive outcomes for treating complex AFib casesNew data from the Volt CE Mark Extension Cohort trial for the Volt™ PFA System, demonstrate the strong safety, efficacy and efficiency of treatment of AFib cases for posterior wall ablationTwo new conduction system pacing studies showcase initial results of Abbott's investigational UltiSynq™ CSP implantable cardioverter-defibrillator lead and a fi
- SECSEC Form S-8 filed by Abbott LaboratoriesS-8 - ABBOTT LABORATORIES (0000001800) (Filer)
ABT FAQ
7 questionsWhat does Abbott Laboratories do?
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo...Where does ABT stock trade?
Abbott Laboratories (ABT) is listed on NYSE.What sector and industry is ABT in?
Abbott Laboratories operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.Does ABT pay a dividend?
ABT's most recent ex-dividend date was 2026-04-15 with a cash dividend of $0.63 per share. No future ex-date is on file yet.What are analysts saying about ABT?
Abbott Laboratories has had 8 recent analyst actions on file. The most recent action was from Daiwa Securities: Neutral on 2026-04-22.What companies are similar to ABT?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare ABT side-by-side with any of them on Quantisnow.How can I track ABT on Quantisnow?
Quantisnow aggregates Abbott Laboratories's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ABT to receive live email and push alerts on every new disclosure.